DBV Technologies (DBVT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.13
- Estimate
- -$0.15
- Surprise
- +14.9%
- Revenue (period 2026-09-30)
- $1.6M
- Score today
- 4.2/10
Revenue source: xbrl.
How the report landed
DBV Technologies (DBVT) reported a narrower loss than forecast — adjusted EPS of -$0.13 against the -$0.15 estimate (a 14.9% beat on a still-unprofitable quarter).
Coverage in the report window
- Guggenheim Maintains Buy Rating on DBV Technologies, Lowers Price Target — fiscal.ai, 2026-10-30
- Guggenheim Maintains Buy on DBV Technologies, Lowers Price Target to $46 — benzinga, 2026-10-30
- Citizens Maintains Market Outperform on DBV Technologies, Lowers Price Target to $47 — benzinga, 2026-10-29
Where TrendMatrix's rating stands now
TrendMatrix currently rates DBVT Sell at 4.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +14.9% surprise compares with a +4.9% four-quarter average. Next scheduled report: 2027-03-25.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive insider activity
What argues against it
- Concentration risk — Pipeline: Viaskin technology platform
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1)
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.42
- Price target
- $11.85
- Stop
- $8.76
- Upside to target
- +25.8%
Model outputs from TrendMatrix’s engine as of 2026-11-19 — shown for context, not personalized investment advice.
DBVT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $608.3M
- P/E (fwd)
- -24.9
- 52-week range
- $8.63–$26.18
- Off 52-week high
- 64.0%
- RSI (14)
- 49
- Volume vs avg
- 0.74×
- Score today
- 4.2/10